Related Experiment Video
Updated: Jun 16, 2026
12:04
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
Published on: March 10, 2023
CLINICAL AND MOLECULAR GENETIC CHARACTERISTICS OF POLYCYTHEMIA VERA AND CURRENT TREATMENT APPROACHES
F Khalilova1, A Kerimov1, G Kerimova1
1National Hematology and Blood Transfusion Center, Baku, Azerbaijan.
Georgian Medical News
|June 14, 2026
Summary
Masked polycythemia vera (mPV) patients experienced more thromboembolic events (TE) despite better treatment response. Timely diagnosis and treatment are crucial for mPV outcomes.
Area of Science:
- Hematology
- Oncology
- Clinical Medicine
Background:
- Polycythemia vera (PV) diagnosis relies on WHO criteria, potentially excluding patients with low hemoglobin (HGB).
- This necessitates differentiating overt PV (oPV) and masked PV (mPV) for appropriate management.
- Analyzing these forms is key to understanding disease heterogeneity.
Purpose of the Study:
- To distinguish between overt PV (oPV) and masked PV (mPV).
- To investigate thrombotic risk, JAK2V617F allele burden (AB), and treatment efficacy in oPV vs. mPV across risk groups.
- To compare thromboembolic events (TE) and hematologic response (HR) between oPV and mPV.
Main Methods:
- A cohort study with retrospective and prospective components.
- 209 PV patients were classified into oPV (136) and mPV (73) groups.
- Hemogram parameters, AB, risk stratification, TE, and HR were analyzed and compared between groups and treatment regimens.
Main Results:
- Thromboembolic events (TE) were more frequent in mPV (p<0.01).
- JAK2V617F allele burden (AB) differed significantly between oPV and mPV in the low-risk group (p=0.001).
- Masked PV (mPV) demonstrated significantly higher overall hematologic response (HR) rates compared to oPV (p = 0.003), particularly with phlebotomy/aspirin and hydroxyurea treatments.
Conclusions:
- Despite higher TE rates in mPV, potentially due to delayed diagnosis, mPV shows superior treatment response compared to oPV.
- The higher platelet (PLT) count in mPV warrants further investigation regarding thrombosis risk.
- Emphasizes the critical importance of timely and aggressive treatment for masked polycythemia vera.
Related Concept Videos
01:27Disorders of Erythrocytes
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:14Erythropoiesis
Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...